<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>253138</rcn>
  <id>101112948</id>
  <acronym>PeptiCHIP</acronym>
  <teaser>Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond.The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of...</teaser>
  <objective>Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond.
The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of triggering an efficient immune response against cancer. Currently there is no standard method to identify antigens and the few methods available have significant limitations by being quite long, complicated and resource demanding. In response to this clear technological and market gap, Valo Therapeutics (ValoTx, an immunotherapy development company) is introducing PeptiCHIP, i.e. an innovative microfluidic immunopurification device and a peptide prioritisation algorithm to identify the most relevant (neo)antigens to stimulate the immune system and thus increase the chance of success of the immunotherapy. PeptiCHIP can be adapted and used to identify antigens related to any disease. The Proof of Concept (PoC) was successfully demonstrated at University of Helsinki. The IP was protected and ValoTx has full rights to further develop, exploit, and commercialize PeptiCHIP. This EIC Transition project will allow further technology development, testing, validating, and demonstrating it pre-clinically, generating evidence to convince investors and stakeholders, as well as to prepare an extensive and solid transition-to-market plan (T2MP). By being accurate, fast, low-cost, easy to use and working with very small amounts of samples, PeptiCHIP will have great impact in: 1) Research: for discovery &amp; new therapies development since identification of antigens allows the understanding of diseases &amp; immune response mechanisms; 2) Industry: for therapy development &amp; translation into clinical use since the antigens identification &amp; prioritization is a critical step to produce therapies tailored for each patient to ensure responsiveness; 3) Clinic: for patient assessment &amp; immunotherapy tailoring.</objective>
  <title>Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization</title>
  <totalCost>2226280</totalCost>
  <ecMaxContribution>2226280</ecMaxContribution>
  <startDate>2023-04-01</startDate>
  <endDate>2025-09-30</endDate>
  <ecSignatureDate>2023-03-13</ecSignatureDate>
  <duration>30</duration>
  <status>SIGNED</status>
  <keywords>Neoantigens, Oncology, Immunotherapy, Cancer treatment, immune response, immunopeptidomics, proteomics</keywords>
  <identifiers>
    <grantDoi>10.3030/101112948</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2025-10-20 17:38:03</sourceUpdateDate>
  <contentCreationDate>2023-07-11 15:49:42</contentCreationDate>
  <contentUpdateDate>2025-11-19 10:22:21</contentUpdateDate>
  <lastUpdateDate>2025-11-19 10:22:26</lastUpdateDate>
  <relations>
    <associations>
      <call source="corda" type="relatedMasterCall">
        <rcn>55631</rcn>
        <title>HORIZON-EIC-2022-TRANSITION-01</title>
        <identifier>HORIZON-EIC-2022-TRANSITION-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55631</rcn>
        <title>HORIZON-EIC-2022-TRANSITION-01</title>
        <identifier>HORIZON-EIC-2022-TRANSITION-01</identifier>
      </call>
      <organization netEcContribution="2226280" totalCost="2226280" source="corda" order="1" ecContribution="2226280" terminated="false" sme="true" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1980969</rcn>
        <id>885471970</id>
        <vatNumber>FI27686954</vatNumber>
        <legalName>VALO THERAPEUTICS OY</legalName>
        <shortName>Valo Therapeutics Oy</shortName>
        <address>
          <street>VIIKINKAARI 6</street>
          <city>Helsinki</city>
          <postalCode>00790</postalCode>
          <country>FI</country>
          <geolocation>60.2265517,25.01371530361569</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode>/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Helsinki-Uusimaa</name>
              <rcn>1465369</rcn>
              <nutsCode>FI1B1</nutsCode>
              <parents>
                <region>
                  <name>Helsinki-Uusimaa</name>
                  <rcn>1464932</rcn>
                  <nutsCode>FI1B</nutsCode>
                  <parents>
                    <region>
                      <name>Manner-Suomi</name>
                      <rcn>256383528</rcn>
                      <nutsCode>FI1</nutsCode>
                      <parents>
                        <region>
                          <name>Finland</name>
                          <rcn>256543272</rcn>
                          <nutsCode>FI</nutsCode>
                          <euCode>FI</euCode>
                          <isoCode>FI</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Finland</name>
              <rcn>256543272</rcn>
              <nutsCode>FI</nutsCode>
              <euCode>FI</euCode>
              <isoCode>FI</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706907</rcn>
        <id>HORIZON_HORIZON-EIC-2022-TRANSITIONOPEN-01</id>
        <code>HORIZON-EIC-2022-TRANSITIONOPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Transition Open 2022</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1176000</rcn>
        <id>101112948_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - PeptiCHIP (Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization)</title>
        <description>periodic</description>
        <teaser>Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond. The core of immunotherapy stands in identifying tumour-specific fingerprints – the neoantigens – that are peptides expressed uniquely by cancer cells, capable...</teaser>
        <sourceUpdateDate>2024-10-10 22:30:39</sourceUpdateDate>
        <contentUpdateDate>2024-10-21 15:38:18</contentUpdateDate>
        <relations>
          <associations>
            <webItem type="relatedResultAttachment" source="corda">
              <language>en</language>
              <availableLanguages>en,any</availableLanguages>
              <uri>/docs/results/horizon/101112/101112948_PS/picture-1.png</uri>
              <alternativeText>PeptiCHIP workflow simplified</alternativeText>
              <mimetype>image/png</mimetype>
              <size>134144</size>
            </webItem>
          </associations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/23/49/315/997</code>
        <title>biomolecules</title>
        <displayCode>/natural sciences/biological sciences/biochemistry/biomolecules</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-EIC</code>
        <title>HORIZON EIC Grants</title>
        <description>HORIZON EIC Grants</description>
        <displayCode>/HORIZON EIC Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>